Core Viewpoint - EQV Ventures Acquisition Corp. has received shareholder approval for its business combination with Presidio Investment Holdings LLC, a company focused on optimizing mature oil and gas assets in the U.S. [2][4] Company Overview - Presidio is headquartered in Fort Worth, TX, and operates mature oil and gas wells across the Mid-Continent, focusing on optimizing existing production and generating sustainable cash flow from low-decline, producing assets [5]. - EQV Ventures Acquisition Corp. is a special purpose acquisition company formed to merge with businesses, specifically in the oil and gas sector, and currently owns and operates over 3,500 wells across 10 states [7]. Transaction Details - The business combination is expected to close on or about March 4, 2026, with shares of the combined entity anticipated to trade on NYSE under the symbol "FTW" starting March 5, 2026 [3]. - Following the transaction's closing, Presidio plans to announce formal dividend timing details aligned with its shareholder return strategy, which emphasizes a capital-light platform with minimal reinvestment requirements [4].

Core Viewpoint - Rocket Lab Corporation successfully launched its latest hypersonic test mission for the Department of War's Defense Innovation Unit, marking a significant advancement in hypersonic technology for the U.S. and its allies [1][2]. Group 1: Launch Details - The mission "That's Not A Knife" took off on February 27, 2026, at 7:00 p.m. Eastern from Rocket Lab Launch Complex 2 in Virginia, representing the second successful hypersonic test mission for the DIU in three months and the seventh overall HASTE launch [2]. - The mission deployed DART AE, a scramjet-powered aircraft developed by Hypersonix, into a suborbital hypersonic flight environment at several times the speed of sound [2]. Group 2: Mission Success and Impact - Rocket Lab has achieved 100% mission success across all HASTE launches, establishing itself as a premier commercial test platform for hypersonic systems within a short span of under two years since its inaugural launch [3]. - The HASTE platform is noted for its operational speed, cost-effectiveness, and versatility, significantly advancing hypersonic innovation and technology readiness for national defense [3]. Group 3: Industry Statements - Brian Rogers, Vice President of Global Launch Services at Rocket Lab, emphasized the importance of regular HASTE launches in accelerating hypersonic readiness for the nation [4]. - Matt Hill, CEO of Hypersonix, highlighted that the successful flight of DART AE validates years of engineering and preparation, moving towards operationally relevant reusable hypersonic capabilities [4]. Group 4: Company Overview - Rocket Lab is a leading space company providing launch services, spacecraft, payloads, and satellite components for commercial, government, and national security markets [5]. - The company’s Electron rocket is recognized as the world's most frequently launched orbital small rocket, while the HASTE rocket offers hypersonic test launch capabilities for the U.S. government and allies [5].

Core Viewpoint - YY Group Holding Limited has entered into an At The Market Sales Agreement to offer and sell up to US$20 million of its Class A Ordinary Shares through designated sales agents [1][2]. Group 1: Offering Details - The shares will be sold at market prices through various methods, including direct sales on The Nasdaq Capital Market and privately negotiated transactions [2]. - The company is not obligated to sell any shares under the ATM Agreement and may suspend or terminate the offering at any time [2]. - Approximately $0.4 million of the net proceeds will be used to satisfy outstanding debt obligations, while additional proceeds will be allocated for general corporate purposes, including business diversification and capital expenditures [2]. Group 2: Regulatory Information - The offering is made under the company's shelf registration statement on Form F-3, which was filed with the U.S. Securities and Exchange Commission on April 23, 2025, and declared effective on April 30, 2025 [3]. Group 3: Company Overview - YY Group Holding Limited is a technology-enabled platform providing flexible workforce solutions and integrated facility management services across Asia and beyond [6]. - The company operates in two core verticals: on-demand staffing and integrated facility management, serving industries such as hospitality, logistics, retail, and healthcare [6]. - YY Group leverages proprietary digital platforms and IoT-driven systems to meet fluctuating labor demands and maintain high-performance environments [7].

Core Viewpoint - Brookfield Property Partners has filed its 2025 annual report on Form 20-F, which includes audited financial statements for the year ending December 31, 2025, with the SEC and Canadian securities authorities [1] Group 1: Company Overview - Brookfield Property Partners is recognized as one of the world's leading real estate companies, owning and operating significant properties in major global markets [2] - The company's diverse portfolio encompasses various sectors, including office, retail, multifamily, logistics, hospitality, single-family rentals, manufactured housing, student housing, and self-storage [2] - Brookfield Property Partners operates as a subsidiary of Brookfield Corporation, which is listed on both NYSE and TSX [2]

Core Viewpoint - The U.S. FDA has granted accelerated approval for YUVIWEL (navepegritide), the first once-weekly treatment for increasing linear growth in children aged 2 and older with achondroplasia, contingent upon further verification of clinical benefits in confirmatory trials [1][9]. Company Overview - Ascendis Pharma A/S is a global biopharmaceutical company focused on innovative therapies using its TransCon technology platform, headquartered in Copenhagen, Denmark [17]. Product Details - YUVIWEL is a prodrug of C-type natriuretic peptide (CNP) designed to provide continuous systemic exposure to CNP, counteracting overactive FGFR3 signaling in achondroplasia [2]. - The approval is based on data from three randomized, double-blind, placebo-controlled clinical trials, including pivotal data from the ApproaCH Trial [3][4]. Market Impact - YUVIWEL is expected to be commercially available in the early part of Q2 2026, with a suite of patient services planned through the Ascendis Signature Access Program (A.S.A.P.) [4][6]. - The FDA also granted a Rare Pediatric Disease Priority Review Voucher in connection with the approval, which can expedite future drug applications [5]. Community Engagement - Advocacy groups, such as Little People of America, emphasize the importance of including the voices of individuals with dwarfism in discussions about treatment options like YUVIWEL [3].

Core Perspective - OpGen, Inc. has rebranded itself as CapForce Inc. to align with its new focus on digital investment banking and financial technology sectors [1] Company Overview - CapForce Inc. provides fintech-enabled digital investment banking services targeting global high-growth mid-sized private companies with market capitalizations between $1 billion and $10 billion [2] - The company aims to serve small-cap and mid-cap stocks that are often overlooked by larger investment banks [2] - CapForce is developing a digital investment banking platform that includes AI-powered asset and wealth management services, cross-border securities activities, and technology-driven capitalization table management solutions [2] - The controlling shareholder, AEI Capital Group, manages over $7 billion in assets under management and focuses on global growth equity strategies [2]

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. NOT FOR DISTRIBUTION TO UNITED STATES NEW ...

Core Viewpoint - Avalon GloboCare Corp. has successfully closed a private placement, raising approximately $3.25 million, with potential additional proceeds of up to $6.5 million from warrants [1][3]. Group 1: Financial Details - The private placement involved the issuance and sale of 6,372,550 shares of common stock at a purchase price of $0.51 per share, along with Series A-1 and A-2 warrants [1]. - The gross proceeds from the offering were approximately $3.25 million before deducting fees and expenses, with potential additional gross proceeds of approximately $6.5 million if the warrants are fully exercised [3]. - The net proceeds from the offering will be used for debt repayment, working capital, and general corporate purposes [3]. Group 2: Warrants Information - Series A-1 warrants will expire five years from stockholder approval, while Series A-2 warrants will expire eighteen months from stockholder approval [1]. - The warrants have an exercise price of $0.51 per share and will be exercisable upon stockholder approval [1]. Group 3: Company Overview - Avalon GloboCare Corp. is focused on developing precision diagnostic consumer products and generative AI publishing and software [1]. - The company is advancing AI systems through its subsidiary, Avalon Quantum AI LLC, and is expanding its intellectual property in cellular therapy and generative AI [6]. - Avalon is also marketing the KetoAir™ breathalyzer device, registered as a Class I medical device with the FDA, and plans to pursue additional diagnostic applications [6].

Core Viewpoint - Femasys Inc. has granted stock options to two new non-executive employees as part of their employment inducement strategy, reflecting the company's commitment to expanding its workforce and enhancing its innovative capabilities in the biomedical sector [1][2]. Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally through a broad, patent-protected portfolio of therapeutic and diagnostic products [3]. - The company is actively commercializing its lead product innovations in the U.S. and key international markets, with a focus on enhancing fertility treatment options and permanent birth control solutions [3]. Product Innovations - Femasys' fertility portfolio includes: - FemaSeed Intratubal Insemination (ITI), which has demonstrated more than double the pregnancy rates of traditional IUI with a comparable safety profile [3]. - FemSperm, a sperm preparation and analysis product line [3]. - FemVue, a companion diagnostic for fallopian tube assessment [3]. - FemBloc is the first and only non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe, the UK, and New Zealand in 2025 [4]. - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, with initial clinical trials showing compelling effectiveness and high satisfaction rates [4]. Stock Options and Employment Strategy - Femasys granted options to purchase 185,000 shares at exercise prices of $0.50 and $0.57, equal to the closing stock price on the employment date [2]. - The stock options will vest 25% on the first anniversary of employment, with the remaining shares vesting 25% each year over the next three years, contingent on continued employment [2].

Core Viewpoint - Orca Energy Group Inc. has reached an agreement with Swala Oil and Gas (Tanzania) plc to discontinue legal proceedings and refer disputes to confidential arbitration [1] Group 1: Legal Agreement - The Orca Group and Swala have agreed to discontinue Swala's proceedings against Orca before the High Court of Tanzania [1] - The anti-suit injunction filed by the Orca Group against Swala in the High Court of England and Wales has been stayed [1] - Any disputes will be referred to arbitration under the Arbitration Rules of the London Court of International Arbitration, with London as the arbitration seat [1] Group 2: Company Overview - Orca Energy Group Inc. is engaged in natural gas development and supply in Tanzania through its subsidiary PanAfrican Energy Tanzania Limited [2] - The company trades on the TSX Venture Exchange under the symbols ORC.A and ORC.B [2]